Kenneth Thompson is the founder of Dianthus Therapeutics. Dianthus Therapeutics has raised $100M in total funding. Latest round: Series A.
Kenneth Thompson is an executive officer at Dianthus Therapeutics, a biotechnology company focused on developing next-generation antibody complement therapeutics. The company aims to treat severe and rare autoimmune diseases, with its lead program, DNTH103, being a potent monoclonal antibody targeting complement C1s. Dianthus Therapeutics launched with a $100 million Series A financing co-led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company.
Full founder directory · Investor directory · Company funding database · Fundraising library